Acute Myelogenous Leukemia Clinical Trial
Official title:
Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsuitable for Fully Myeloablative Transplantation
RATIONALE: Giving chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total
body irradiation, before peripheral blood stem cell transplant helps stop the growth of
cancer cells. It may also stop the patient's immune system from rejecting the donor's stem
cells. When the healthy stem cells and natural killer (NK) cells from a donor are infused
into the patient they may help the patient's bone marrow make stem cells, red blood cells,
white blood cells, and platelets. Giving IL-2 (aldesleukin) after NK cell infusion may
stimulate them to kill any remaining cancer cells.
PURPOSE: This phase I/II (currently enrolling in phase II) trial is studying how well a donor
natural killer cell infusion works in treating patients who are undergoing donor stem cell
transplant for acute myeloid leukemia.
OBJECTIVES:
Primary
- To determine the disease-free survival at 6 months and 1 year in patients with high-risk
myeloid malignancies who undergo a reduced-intensity haploidentical hematopoietic stem
cell transplantation (HSCT) supplemented with donor natural killer (NK) cells.
Secondary
- To evaluate the in vivo expansion of a donor CD3- CD19- selected NK cell product
administered after a preparative regimen of cyclophosphamide, fludarabine, and total
body irradiation (TBI) and HSCT in these patients.
- To determine the rate of graft failure defined by absolute neutrophil count (ANC) <
500/mm³ by day 28.
- To determine the incidence of grade III-IV acute graft-versus-host disease (GVHD) at 6
months.
- To determine the rate of treatment-related mortality at day 100.
- To determine the incidence of chronic GVHD at 12 months.
- To determine the incidence of disease relapse at 12 months.
- To determine the incidence of post-transplant lymphoproliferative disorder at 12 months.
Correlative
- To correlate immune reconstitution of the in vivo expanded haploidentical NK cells with
clinical outcomes.
OUTLINE: This is an open-label study.
Patients receive fludarabine intravenous (IV) over 1 hour on days -18 to -14 and
cyclophosphamide IV over 2 hours on days -16 and -15. Patients receive cyclosporin A on Day
-15 through Day -8. Patients undergo total body irradiation on day -13. Patients then receive
an infusion of donor natural killer cells on day -12 and interleukin-2 subcutaneously on
alternating days between days -12 to -2. Patients receive thymoglobulin (ATG) and undergo
allogeneic peripheral blood stem cell transplantation on day 0.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01200355 -
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02543879 -
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01681537 -
Lenalidomide Plus Chemotherapy for AML
|
Phase 1 | |
Completed |
NCT01385423 -
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
|
Phase 1 | |
Terminated |
NCT01193400 -
Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years
|
Phase 2 | |
Completed |
NCT00995332 -
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
|
Phase 1/Phase 2 | |
Completed |
NCT00981240 -
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
|
Phase 1 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00726934 -
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
|
N/A | |
Completed |
NCT00378534 -
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
|
Phase 2 | |
Completed |
NCT01031498 -
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT00789256 -
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
|
N/A | |
Completed |
NCT00098033 -
Investigation of Clofarabine in Acute Leukemias
|
Phase 2 | |
Completed |
NCT01020539 -
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
|
Phase 1 | |
Not yet recruiting |
NCT04709458 -
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
|
Phase 1 | |
Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
Terminated |
NCT02203773 -
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
|
Phase 1 |